Life after Lyxumia: Ex-Zealand CEO Solomon's next quest is to cure HIV
This article was originally published in Scrip
Executive Summary
David Horn Solomon spent six years heading up Zealand Pharma, developer of the GLP-1 agonist Lyxumia (lixisenatide), which has travelled a bumpy road in the hands of licensing partner Sanofi. He is now CEO of Bionor Pharma, a company that is hoping to make headway with its HIV vaccine. Rather a challenge, but Dr Solomon believes the company is a clear two years ahead of the competition and with his guidance stands a real chance of being the first to tackle the 'What's next?' question in the treatment of HIV.